Investigating the Efficacy and Safety of Oral Cicaglocal on Wound Healing After Mohs Surgery in Patients With Skin Cancer: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

BACKGROUND

Mohs micrographic surgery is the gold standard treatment for skin cancers in cosmetically sensitive anatomic areas, with a cure rate close to 100%. Managing post-Mohs surgery wounds can pose challenges, particularly in elderly patients. This study evaluates the Cicaglocal drug, a supplement with bromelain, Centella asiatica, hyaluronan, vitamins, and minerals, for enhancing wound healing post-Mohs surgery.

METHOD: This double-blinded, randomized clinical trial conducted at Al-Zahra Hospital in 2023 involved 24 patients aged 50-80 with SCC or BCC undergoing Mohs surgery. Patients were randomized into two groups Cicaglocal and placebo. Treatments were administered postoperatively, and outcomes such as erythema reduction, early healing score (EHS), full recovery, and patient and physician satisfaction levels were evaluated 7 and 14 days after initiation. Data were collected through clinical assessments and standardized wound photographs.

RESULT: Oral Cicaglocal demonstrated significantly improved outcomes compared to their respective placebo groups in terms of erythema score, EHS, full recovery score, and patient and physician satisfaction levels.

CONCLUSION

Cicaglocal can enhance wound healing and lead to improved clinical outcomes following Mohs micrographic surgery.